Buprenorphine TDS: The clinical development - Rationale and results

International Journal of Clinical Practice, Supplement

Volumn , Issue 133, 2003, Pages 15-18

  Radbruch, Lukas ^a   Vielvoye Kerkmeer, Ans ^b  

^a UNIVERSITY OF COLOGNE   (Germany)

^b LEIDEN UNIVERSITY   (Netherlands)

Author keywords

Analgesia; Buprenorphine; Matrix patch; Morphine; Opioids; Transdermal

Indexed keywords

BUPRENORPHINE; MORPHINE; OPIATE; PLACEBO;

ANALGESIC ACTIVITY; CANCER PAIN; CHRONIC PAIN; CLINICAL TRIAL; CONFERENCE PAPER; DISEASE SEVERITY; DOSE RESPONSE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG TOLERABILITY; ERYTHEMA; FOLLOW UP; HUMAN; LOW DRUG DOSE; MEDICAL PRACTICE; NAUSEA; OPEN STUDY; PRIORITY JOURNAL; PRURITUS; SIDE EFFECT; SLEEP; VERTIGO; VOMITING;

ANALGESICS, OPIOID; ATTITUDE TO HEALTH; BUPRENORPHINE; HUMANS; MULTICENTER STUDIES; PAIN; RANDOMIZED CONTROLLED TRIALS; TREATMENT OUTCOME;

EID: 0037301405     PISSN: 1368504X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (5)

1. Huang P, Kehner GB, Cowan A, Liu-Chen LY. Comparison of pharmacological activities of buprenorphine and norbuprenorphine: norbuprenorphine is a potent opioid agonist. J Pharmacol Exp Ther 2001; 297: 688-695.
2. Zenz M, Strumpf M, Tryba M. Long-term oral opioid therapy in patients with chronic nonmalignant pain. J Pain Symptom Manage 1992;7:69-77.
3. Böhme K. Buprenorphine in a transdermal therapeutic system - a new option. Clin Rheumatol 2002; Suppl 1: S13-S16.
4. Cowan A, Lewis JW, MacFarlane IR. Agonist and antagonist properties of buprenorphine, a new antinociceptive agent. Br J Pharmacol 1977; 60: 537-545.
5. Lewis JW. Buprenorphine. Drug Alcohol Depend 1985; 14: 363-372.